Enhanced apoptosis and transforming growth factor-β1 expression in colorectal adenomas and carcinomas after sulindac therapy
Enhanced apoptosis and transforming growth factor-β1 expression in colorectal adenomas and carcinomas after sulindac therapy
复制标题
舒林酸治疗后结直肠腺瘤和癌中细胞凋亡和转化生长因子-β1 表达增强
DOI:
10.1007/bf02235490
复制
发表时间:
2001
影响因子:
3.9
通讯作者:
N. Nagasue
中科院分区:
文献类型:
--
作者:
R. Masunaga;H. Kohno;D. Dhar;T. Kotoh;H. Tabara;M. Tachibana;H. Kubota;N. Nagasue
PURPOSE: We tried to elucidate the effects of sulindac on human colorectal carcinoma. METHODS: Sulindac (300 mg/day) was administered for two weeks before operation to 33 patients with sporadic colorectal carcinoma (Sulindac Group). Resected specimens were used to detect apoptosis by terminal dUTP nick end labeling and transforming growth factor (TGF)-β1 expression by immunohistochemistry. The results were compared with those from the historical Control Group. Twenty-nine available preoperative biopsies taken from carcinomas before sulindac prescription and 22 concurrent colorectal adenomas (9 and 13 in Sulindac and Control Groups, respectively) in the resected specimen were also examined regarding TGF-β1 expression. RESULTS: In the resected carcinomas and adenomas, more frequent apoptosis and higher TGF-β1 scores were observed in the Sulindac Group than in the Control Group. Overexpression of TGF-β1 and apoptosis occurred in the same region in adenomas but not in carcinomas. A positive correlation between TGF-β1 scores and apoptotic frequency was found in adenomas (P=0.01,ρ=0.91) but not in carcinomas (P=0.89,ρ=0.03). CONCLUSION: We conclude that sulindac induces apoptosis in human colorectal carcinomas as well as in adenomas. Also, one of the antineoplastic effects of sulindac might be mediated by upregulating TGF-β1 expression, particularly in colorectal adenomas.
DOI:
--
发表时间:
2007
期刊:
Prog Neuropsychopharmacol Biol Psychiatry 31(1)
影响因子:
--
作者:
Okada;K.;et. al.
通讯作者:
et. al.